MedTrace Logo

The Effect of Novel D3 Use as a Mouthwash in COVID-19 Patients

NCT07068282 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-07-16

No results posted yet for this study

Summary

The PI's goal of this \[interventional/clinical trial\] is to \[explore the antiviral properties of vitamin D3 on saliva samples collected before and after the use of a vitamin D3 mouthwash\] in \[ adult participants, both genders, with COVID-19 who tested positive on a swab test\]. The main question\[s\] aims to answer \[is\]:

\[Assess the antiviral potential of a novel vitamin D-based mouthwash in COVID-19-positive participants\].

PI will compare both \[Control group: saliva only- before use of mouthwash\], and the \[study group: after use of the mouthwash in saliva\] to see if there is \[any veridical effect present in saliva after running lab tests\].

Participants will \[self-collect saliva in a given tube (color coded orange), then 10-15 minutes later or more, participants will swish with D3 mouthwash, and will give another sample \[saliva + mouthwash\] in another (green labeled tube). For each participant, each of the following will be given:

* 2 collecting tubes: orange labeled tube (for saliva collection only) and green labeled tube (for saliva collection after mouthwash use).
* The vial containing vitamin D3 mouthwash.

Conditions

  • Corona Virus Disease 19 (COVID-19)

Interventions

DRUG

Cholecalciferol (vitaminD3)

Vitamin D3 mouthwash was prepared for COVID-19 participants, to compare between the saliva only (control group), and with the use of mouthwash in saliva after the participants swish for 60 seconds (experimental group) and compare the effect of vitamin D over the virus in saliva, from both groups by testing via RAT and R-PCR.

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-24
Primary Completion
2025-01-25
Completion
2025-02-12

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07068282 on ClinicalTrials.gov